Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Myc Proto Oncogene Protein (MYC) protein is a transcription factor that activates the expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor.

The MYC pipeline market research report provides comprehensive information on the MYC targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, the latest news as well as press releases. Additionally, the report provides an overview of key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Therapy Areas in the MYC Pipeline Products Market

The key therapy area in the MYC pipeline products market is oncology.

Key Mechanisms of Action in the MYC Pipeline Products Market

The key mechanism of action in the MYC pipeline products market is Myc Proto Oncogene Protein Inhibitor.

Key Routes of Administration in the MYC Pipeline Products Market

The key routes of administration in the MYC pipeline products market are intravenous and oral.

MYC Pipeline Products Market Analysis by Routes of Administration

MYC Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the MYC Pipeline Products Market

The key molecule types in the MYC pipeline products market are small molecule, oligonucleotide, recombinant peptide, synthetic peptide, and peptide.

MYC Pipeline Products Market Analysis by Molecule Types

MYC Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the MYC Pipeline Products Market

Some of the major companies in the MYC pipeline products market are Anima Biotech Inc, Arrakis Therapeutics Inc, Arvinas Inc, Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience Pty Ltd, Erasca Inc, Escend Pharmaceuticals Inc, Gibson Oncology LLC, and Kintor Pharmaceutical Ltd.

MYC Pipeline Products Market Analysis by Companies

MYC Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

MYC Pipeline Products Market Report Overview

Key Therapy Areas Oncology
Key Mechanisms of Action Myc Proto Oncogene Protein Inhibitor
Key Routes of Administration Intravenous and Oral
Key Molecule Type Small Molecule, Oligonucleotide, Recombinant Peptide, Synthetic Peptide, and Peptide
Major Companies Anima Biotech Inc, Arrakis Therapeutics Inc, Arvinas Inc, Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience Pty Ltd, Erasca Inc, Escend Pharmaceuticals Inc, Gibson Oncology LLC, and Kintor Pharmaceutical Ltd

Scope

  • The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
  • The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
  • The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Anima Biotech Inc
Arrakis Therapeutics Inc
Arvinas Inc
Biogenera SpA
Ceptur Therapeutics Inc
Cothera Bioscience Pty Ltd
Erasca Inc
Escend Pharmaceuticals Inc
Gibson Oncology LLC
Kintor Pharmaceutical Ltd
Kronos Bio Inc
MecRx Pty Ltd
Omega Therapeutics Inc
OncoViRx LLC
Origenis GmbH
Peptomyc SL
PYC Therapeutics Ltd
Recursion Pharmaceuticals Inc
Sapience Therapeutics Inc
SyntheX Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Overview

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Companies Involved in Therapeutics Development

Anima Biotech Inc

Arrakis Therapeutics Inc

Arvinas Inc

Biogenera SpA

Ceptur Therapeutics Inc

Cothera Bioscience Pty Ltd

Erasca Inc

Escend Pharmaceuticals Inc

Gibson Oncology LLC

Kintor Pharmaceutical Ltd

Kronos Bio Inc

MecRx Pty Ltd

Omega Therapeutics Inc

OncoViRx LLC

Origenis GmbH

Peptomyc SL

PYC Therapeutics Ltd

Recursion Pharmaceuticals Inc

Sapience Therapeutics Inc

SyntheX Inc

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Drug Profiles

Amy-22 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BGA-003 – Drug Profile

Product Description

Mechanism Of Action

Drugs to Inhibit MYC for Breast Cancer – Drug Profile

Product Description

Mechanism Of Action

ERAS-11 – Drug Profile

Product Description

Mechanism Of Action

ES-4000 – Drug Profile

Product Description

Mechanism Of Action

GT-19077 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GT-19630 – Drug Profile

Product Description

Mechanism Of Action

Myc – Drug Profile

Product Description

Mechanism Of Action

History of Events

MYC – Drug Profile

Product Description

Mechanism Of Action

MYC (Oncology) – Drug Profile

Product Description

Mechanism Of Action

History of Events

NOV-1701 – Drug Profile

Product Description

Mechanism Of Action

Oligonucleotides to Inhibit MYC for Hepatocellular Carcinoma and Non Small Cell Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

OMO-101 – Drug Profile

Product Description

Mechanism Of Action

OMO-103 – Drug Profile

Product Description

Mechanism Of Action

History of Events

OTX-2002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PC-002p – Drug Profile

Product Description

Mechanism Of Action

REC-0162977 – Drug Profile

Product Description

Mechanism Of Action

REC-841 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Target c-Myc for Multiple Myeloma – Drug Profile

Product Description

Mechanism Of Action

Small Molecules 3 to Inhibit C-Myc for Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit c-Myc for Oncology – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit C-Myc for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit C-Myc for Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit cMyc for Oncology – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit MYC and TOP1 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

STX-300 – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Inhibit C-Myc for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor – Drug Profile

Product Description

Mechanism Of Action

Target 1 (PPI Modulator) – Drug Profile

Product Description

Mechanism Of Action

History of Events

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Dormant Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Discontinued Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Product Development Milestones

Featured News & Press Releases

Jun 23, 2022: Omega Therapeutics to present new preclinical data for the first epigenomic controller, OTX-2002, for hepatocellular carcinoma at the European Society of Medical Oncology’s 2022 World Congress on Gastrointestinal Cancer

Jun 15, 2022: Omega Therapeutics announces submission of Investigational New Drug application for OTX-2002, an Omega Epigenomic Controller, for MYC driven hepatocellular carcinoma

Apr 08, 2022: Omega Therapeutics presents preclinical data on OTX-2002, first-in-class epigenomic controller, as potential treatment for hepatocellular carcinoma at the AACR Annual Meeting 2022

Mar 08, 2022: Omega Therapeutics to present preclinical data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022

May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial

Mar 17, 2021: Omomyc, a drug developed in Vall d’Hebron, is coming to the clinical trial

Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic

Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting

Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news

Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc

Mar 14, 2019: A new approach to drugging a difficult cancer target

Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer

Nov 16, 2015: Phylogica exceeds gold – standard for treatment of MYC – driven cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Anima Biotech Inc, 2022

Pipeline by Arrakis Therapeutics Inc, 2022

Pipeline by Arvinas Inc, 2022

Pipeline by Biogenera SpA, 2022

Pipeline by Ceptur Therapeutics Inc, 2022

Pipeline by Cothera Bioscience Pty Ltd, 2022

Pipeline by Erasca Inc, 2022

Pipeline by Escend Pharmaceuticals Inc, 2022

Pipeline by Gibson Oncology LLC, 2022

Pipeline by Kintor Pharmaceutical Ltd, 2022

Pipeline by Kronos Bio Inc, 2022

Pipeline by MecRx Pty Ltd, 2022

Pipeline by Omega Therapeutics Inc, 2022

Pipeline by OncoViRx LLC, 2022

Pipeline by Origenis GmbH, 2022

Pipeline by Peptomyc SL, 2022

Pipeline by PYC Therapeutics Ltd, 2022

Pipeline by Recursion Pharmaceuticals Inc, 2022

Pipeline by Sapience Therapeutics Inc, 2022

Pipeline by SyntheX Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.